Development of Prognostic Nomogram Based on Lipid Metabolic Markers and Lactate Dehydrogenase in Non-Metastatic Nasopharyngeal Carcinoma

References

• Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–655. doi:10.1016/S1470-2045(15)70126-9
   PubMed Web of Science ®Google Scholar
• Sun XS, Liu SL, Luo MJ, et al. The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012. Int J Radiat Oncol. 2019;105(3):581–590. doi:10.1016/j.ijrobp.2019.06.2549
   PubMed Web of Science ®Google Scholar
• Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.006
   PubMed Web of Science ®Google Scholar
• Lee AWM, Ng WT, Chan LLK, et al. Evolution of treatment for nasopharyngeal cancer – success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110(3):377–384. doi:10.1016/j.radonc.2014.02.003
   PubMed Web of Science ®Google Scholar
• Lee AWM, Ng WT, Chan ATC. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–3364. doi:10.1200/JCO.2015.60.9347
   PubMed Web of Science ®Google Scholar
• Lam WKJ, Chan KCA. Plasma Epstein–Barr virus DNA as an archetypal circulating tumour DNA marker. J Pathol. 2019;247(5):641–649. doi:10.1002/path.5249
   PubMed Web of Science ®Google Scholar
• Le QT, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr Virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19(8):2208–2215. doi:10.1158/1078-0432.CCR-12-3702
   PubMed Web of Science ®Google Scholar
• Luo W. Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal “unity of ecology and evolution” pathological ecosystem. Theranostics. 2023;13(5):1607–1631. doi:10.7150/thno.82690
   PubMed Web of Science ®Google Scholar
• Muluh TA, Sheng SX, Ying Y. Targeting cancer metabolic vulnerabilities for advanced therapeutic efficacy. Biomed Pharmacother. 2023;162:114658. doi:10.1016/j.biopha.2023.114658
   PubMed Web of Science ®Google Scholar
• Corn KC, Windham MA, Rafat M. Lipids in the tumor microenvironment: from cancer progression to treatment. Prog Lipid Res. 2020;80:101055. doi:10.1016/j.plipres.2020.101055
   PubMed Web of Science ®Google Scholar
• Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1):e20201606. doi:10.1084/jem.20201606
   PubMed Web of Science ®Google Scholar
• Luo X, Cheng C, Tan Z, et al. Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer. 2017;16(1):76. doi:10.1186/s12943-017-0646-3
   PubMed Web of Science ®Google Scholar
• Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun. 2018;38(1):27. doi:10.1186/s40880-018-0301-4
   Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• His M, Zelek L, Deschasaux M, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol. 2014;29(2):119–132. doi:10.1007/s10654-014-9884-5
   PubMed Web of Science ®Google Scholar
• Yang MH, Rampal S, Sung J, et al. The association of serum lipids with colorectal adenomas. Am J Gastroenterol. 2013;108(5):833–841. doi:10.1038/ajg.2013.64
   PubMed Web of Science ®Google Scholar
• Lyu J, Yang N, Guan W, et al. Post-treatment serum triglyceride: an effective biomarker for body fat mass and overall survival in esophageal squamous cell cancer patients treated with chemoradiotherapy. Front Nutr. 2022;9:1050643. doi:10.3389/fnut.2022.1050643
   PubMed Web of Science ®Google Scholar
• Ma C, Wang X, Guo J, Liu P. Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study. Lipids Health Dis. 2021;20(1):69. doi:10.1186/s12944-021-01492-y
   PubMed Web of Science ®Google Scholar
• Peng H, Chen L, Zhang Y, et al. Prognostic value of diabetes in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation Therapy. Sci Rep. 2016;6(1):22200. doi:10.1038/srep22200
   PubMedGoogle Scholar
• Xie Z, Shao Y. The predictive value of serum lipids for eye metastases in male nasopharyngeal carcinoma patients. Biosci Rep. 2020;40(6):BSR20201082. doi:10.1042/BSR20201082
   PubMedGoogle Scholar
• Wang CT, Chen MY, Guo X, et al. Association between pretreatment serum high-density lipoprotein cholesterol and treatment outcomes in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. J Cancer. 2019;10(16):3618–3623. doi:10.7150/jca.32621
   PubMed Web of Science ®Google Scholar
• Wan XB, Wei L, Li H, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur J Cancer. 2013;49(10):2356–2364. doi:10.1016/j.ejca.2013.03.008
   PubMed Web of Science ®Google Scholar
• Li XH, Chang H, Xu BQ, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Med. 2017;6(1):310–319. doi:10.1002/cam4.947
   PubMed Web of Science ®Google Scholar
• Zhao R, Liang Z, Chen K, Zhu X. Nomogram based on inflammatory biomarkers and nutritional indicators for predicting overall survival in locoregionally advanced nasopharyngeal carcinoma. J Inflamm Res. 2022;15:2971–2981. doi:10.2147/JIR.S366299
   PubMed Web of Science ®Google Scholar
• Guo R, Wang S, Hu Y, et al. New parameters of the 8th edition AJCC/UICC T category in nasopharyngeal carcinoma: cervical vertebrae invasion and parotid gland invasion. Clin Transl Med. 2020;10(7). doi:10.1002/ctm2.202
   Web of Science ®Google Scholar
• Hui EP, Li WF, Ma BB, et al. Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol. 2020;31(6):769–779. doi:10.1016/j.annonc.2020.03.289
   PubMed Web of Science ®Google Scholar
• Gihbid A, Benzeid R, Faouzi A, et al. The dynamic change in plasma Epstein–Barr Virus DNA load over a long-term follow-up period predicts prognosis in nasopharyngeal carcinoma. Viruses. 2023;15:66.
   Web of Science ®Google Scholar
• Tan R, Phua SKA, Soong YL, et al. Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Commun. 2020;40(11):564–585. doi:10.1002/cac2.12100
   Web of Science ®Google Scholar
• Guo R, Tang LL, Mao YP, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma: refined TNM Staging for EBV-Related NPC. Cancer. 2019;125(1):79–89. doi:10.1002/cncr.31741
   PubMed Web of Science ®Google Scholar
• Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129(8):65.
   Web of Science ®Google Scholar
• Ackerman D, Tumanov S, Qiu B, et al. Triglycerides promote lipid homeostasis during hypoxic stress by balancing fatty acid saturation. Cell Rep. 2018;24(10):2596–2605.e5. doi:10.1016/j.celrep.2018.08.015
   PubMed Web of Science ®Google Scholar
• Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer Machine: the role of lipid metabolism in cancer. Cell Metab. 2020;31(1):62–76. doi:10.1016/j.cmet.2019.11.010
   PubMed Web of Science ®Google Scholar
• Berrino F, Villarini A, Traina A, et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat. 2014;147(1):159–165. doi:10.1007/s10549-014-3076-6
   PubMed Web of Science ®Google Scholar
• Allott EH, Howard LE, Cooperberg MR, et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2349–2356. doi:10.1158/1055-9965.EPI-14-0458
   PubMed Web of Science ®Google Scholar
• Tan JTM, Bursill CA. The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovasc Res. 2015;106(2):184–193. doi:10.1093/cvr/cvv104
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhu N, Shi Y, et al. Targeting HDL in tumor microenvironment: new hope for cancer therapy. J Cell Physiol. 2021;236(11):7853–7873. doi:10.1002/jcp.30412
   PubMed Web of Science ®Google Scholar
• Ganjali S, Ricciuti B, Pirro M, et al. High-Density lipoprotein components and functionality in cancer: state-of-the-Art. Trends in Endocrinol Metab. 2019;30(1):12–24. doi:10.1016/j.tem.2018.10.004
   PubMed Web of Science ®Google Scholar
• Li J, Chen S, Peng S, et al. Prognostic nomogram for patients with nasopharyngeal carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci. 2018;14.
   Web of Science ®Google Scholar
• Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25(1):35. doi:10.1186/s11658-020-00228-7
   PubMed Web of Science ®Google Scholar
• Liang YL, Zhang Y, Tan XR, et al. A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Nat Commun. 2022;13(1):2996. doi:10.1038/s41467-022-30709-6
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y. MicroRNAs: novel factors in clinical diagnosis and prognosis for nasopharyngeal carcinoma. Acta Pharmacol Sin. 2012;33(8):981–982. doi:10.1038/aps.2012.98
   PubMed Web of Science ®Google Scholar